CN102666512B - 对疾病治疗有用的mek抑制剂 - Google Patents

对疾病治疗有用的mek抑制剂 Download PDF

Info

Publication number
CN102666512B
CN102666512B CN201080053278.5A CN201080053278A CN102666512B CN 102666512 B CN102666512 B CN 102666512B CN 201080053278 A CN201080053278 A CN 201080053278A CN 102666512 B CN102666512 B CN 102666512B
Authority
CN
China
Prior art keywords
compound
mmol
compounds
formula
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080053278.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102666512A (zh
Inventor
乌岱·R·凯尔
马亨德拉·德维查德·朝蒂亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Errol Mike Medical Inc
Original Assignee
ALLOSTEM THERAPEUTICS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALLOSTEM THERAPEUTICS LLC filed Critical ALLOSTEM THERAPEUTICS LLC
Publication of CN102666512A publication Critical patent/CN102666512A/zh
Application granted granted Critical
Publication of CN102666512B publication Critical patent/CN102666512B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CN201080053278.5A 2009-10-13 2010-10-13 对疾病治疗有用的mek抑制剂 Active CN102666512B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25093609P 2009-10-13 2009-10-13
US61/250,936 2009-10-13
PCT/US2010/052514 WO2011047055A2 (en) 2009-10-13 2010-10-13 Novel mek inhibitors, useful in the treatment of diseases

Publications (2)

Publication Number Publication Date
CN102666512A CN102666512A (zh) 2012-09-12
CN102666512B true CN102666512B (zh) 2014-11-26

Family

ID=43876849

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080053278.5A Active CN102666512B (zh) 2009-10-13 2010-10-13 对疾病治疗有用的mek抑制剂

Country Status (10)

Country Link
US (1) US9034861B2 (https=)
EP (1) EP2488507B1 (https=)
JP (1) JP5892612B2 (https=)
KR (1) KR20120094165A (https=)
CN (1) CN102666512B (https=)
AU (1) AU2010306830C1 (https=)
BR (1) BR112012008599A2 (https=)
CA (1) CA2814617C (https=)
ES (1) ES2534358T3 (https=)
WO (1) WO2011047055A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
US11559544B2 (en) 2017-08-23 2023-01-24 Cell Receptor AG Combination of a MAPK/ERK pathway inhibitor and a glycosaminoglycan for the treatment of cancer
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021401282A1 (en) * 2020-12-16 2023-07-13 Mosaica Medicines, Inc. Kinase inhibitors and uses thereof
US12280055B2 (en) 2021-05-27 2025-04-22 Mirati Therapeutics, Inc. Combination therapies
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025147503A1 (en) 2024-01-05 2025-07-10 Pasithea Therapeutics Corp. 10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2-dioxide stereoisomers, and compositions comprising and methods of using the same
TW202542122A (zh) 2024-01-05 2025-11-01 美商帕熙席亞醫療股份有限公司 包含（５ｒ，６ｓ）—１０，１１—二氟—１２—（（２—氟—４—碘苯基）—５，６—二羥基—４，５，６，７—四氫—１１１—螺［苯并［ｂ］［１，５，４］氧雜噻西啶—３，１＇—環丙烷］２，２—二氧化物之固體形式以及包含其之組合物及使用其之方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062191A1 (en) * 2002-01-23 2003-07-31 Warner-Lambert Company Llc N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
CN101124199A (zh) * 2004-07-26 2008-02-13 中外制药株式会社 作为mek抑制物质的5-取代-2-苯基氨基-苯甲酰胺类
CN101495118A (zh) * 2005-07-21 2009-07-29 阿迪亚生命科学公司 Mek的n-(芳基氨基)磺酰胺抑制剂

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ES2153031T4 (es) 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
KR20000067904A (ko) 1996-07-18 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 매트릭스 메탈로프로테아제의 포스피네이트계 억제제
KR20000068248A (ko) 1996-08-23 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐아미노 하이드록삼산 유도체
JP3338064B2 (ja) 1997-01-06 2002-10-28 ファイザー・インク 環状スルホン誘導体
NZ336840A (en) 1997-02-03 2001-01-26 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
EP0960098A1 (en) 1997-02-11 1999-12-01 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
CA2299355C (en) 1997-08-08 2005-09-27 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
GB0131034D0 (en) * 2001-12-28 2002-02-13 Pharmacia & Upjohn Spa Benzocyclodecane derivatives with antitumor activity
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
CA2618218C (en) * 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
JP5269762B2 (ja) 2006-04-18 2013-08-21 アーディア・バイオサイエンシーズ・インコーポレイテッド Ｍｅｋ阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド
KR20090111847A (ko) 2007-01-19 2009-10-27 아디아 바이오사이언스즈 인크. Ｍｅｋ 억제제
EA032294B1 (ru) 2007-07-30 2019-05-31 Арди Байосайенсиз, Инк. Способ получения полиморфной формы производного n-(ариламино)сульфонамида, фармацевтическая композиция, содержащая указанное производное, и способ лечения с помощью указанного производного
CA2924436A1 (en) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use
EP2197428B1 (en) 2007-10-16 2012-01-25 Pharmathen S.A. Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
MX2010011314A (es) 2008-04-14 2010-11-12 Ardea Biosciences Inc Composiciones y metodos de preparacion y uso de las mismas.
CN102134218A (zh) 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062191A1 (en) * 2002-01-23 2003-07-31 Warner-Lambert Company Llc N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
CN101124199A (zh) * 2004-07-26 2008-02-13 中外制药株式会社 作为mek抑制物质的5-取代-2-苯基氨基-苯甲酰胺类
CN101495118A (zh) * 2005-07-21 2009-07-29 阿迪亚生命科学公司 Mek的n-(芳基氨基)磺酰胺抑制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy;Bret B.Friday，等;《Clinical Cancer Research》;20080115;第14卷(第2期);第342-346页 *
MEK Inhibition Enhances Paclitaxel-induced Tumor Apoptosis;Jeffrey P.,等;《The Journal of Biological Chemistry》;20001018;第275卷(第50期);第38953-38956页 *
结直肠癌中MEK2/ERK信号传导通路的研究;张辉，等;《中国普通外科杂志》;20040430;第13卷(第4期);第257-260页 *

Also Published As

Publication number Publication date
US20120208859A1 (en) 2012-08-16
US9034861B2 (en) 2015-05-19
CN102666512A (zh) 2012-09-12
WO2011047055A3 (en) 2011-08-18
EP2488507B1 (en) 2014-12-17
EP2488507A4 (en) 2013-05-01
AU2010306830A1 (en) 2012-05-31
CA2814617A1 (en) 2011-04-21
KR20120094165A (ko) 2012-08-23
BR112012008599A2 (pt) 2019-09-24
WO2011047055A2 (en) 2011-04-21
WO2011047055A8 (en) 2012-05-24
JP2013507453A (ja) 2013-03-04
ES2534358T3 (es) 2015-04-21
AU2010306830B2 (en) 2014-11-06
EP2488507A2 (en) 2012-08-22
CA2814617C (en) 2017-12-19
AU2010306830C1 (en) 2015-05-28
JP5892612B2 (ja) 2016-03-23

Similar Documents

Publication Publication Date Title
CN102666512B (zh) 对疾病治疗有用的mek抑制剂
CN101454004B (zh) 作为mek抑制剂的吡啶酮磺酰胺类和吡啶酮硫酰胺类
CN101808516B (zh) 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
US8648116B2 (en) Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
ES2543608T3 (es) Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de MEK
US8829052B2 (en) Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK
US7842836B2 (en) N-aryl-N'alkyl sulfamides as MEK inhibitors
CN102131771A (zh) 组合物及其制备和使用方法
US20150250762A1 (en) Novel mek inhibitors for treating cardiomyopathies and related conditions
HK1174619A (en) Novel mek inhibitors, useful in the treatment of diseases
TWI481590B (zh) 作為ｍｅｋ抑制劑之ｎ－（芳胺基）磺醯胺（包括多晶型）衍生物及組合物，使用方法及其製備方法
HK1170489A (en) Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1174619

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ALLOMEK THERAPEUTICS LLC

Free format text: FORMER NAME: ALLOSTEM THERAPEUTICS LLC

CP01 Change in the name or title of a patent holder

Address after: American Connecticut

Patentee after: Errol Mike medical Inc.

Address before: American Connecticut

Patentee before: Allostem Therapeutics LLC